To register biosimilars in Taiwan, applicants must submit data proving similarity to the reference product in terms of safety, efficacy, and quality. The process requires comparative clinical trials, pharmacokinetic studies, and compliance with Good Manufacturing Practice (GMP). The TFDA may expedite reviews if biosimilars address unmet medical needs.
